Cargando…

The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies.

The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. The purpose of the validation program was to demonstrate the performance of two versions of the uterotrophic bioassay, the immature female rat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanno, Jun, Onyon, Lesley, Peddada, Shyamal, Ashby, John, Jacob, Elard, Owens, William
Formato: Texto
Lenguaje:English
Publicado: 2003
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241659/
https://www.ncbi.nlm.nih.gov/pubmed/12948896
_version_ 1782125467994685440
author Kanno, Jun
Onyon, Lesley
Peddada, Shyamal
Ashby, John
Jacob, Elard
Owens, William
author_facet Kanno, Jun
Onyon, Lesley
Peddada, Shyamal
Ashby, John
Jacob, Elard
Owens, William
author_sort Kanno, Jun
collection PubMed
description The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. The purpose of the validation program was to demonstrate the performance of two versions of the uterotrophic bioassay, the immature female rat and the adult ovariectomized rat, in four standardized protocols. This article reports the dose-response studies of the validation program; the coded single-dose studies are reported in an accompanying paper. The dose-response study design used five selected weak estrogen agonists, bisphenol A, genistein, methoxychlor, nonylphenol, and o,p -DDT. These weak agonists were administered in a prescribed series of doses to measure the performance and reproducibility of the protocols among the participating laboratories. All protocols successfully detected increases in uterine weights when the weak agonists were administered. Within each protocol, there was good agreement and reproducibility of the dose response among laboratories with each substance. Substance-specific variations were observed in the influence of the route of administration on the uterine response, the potency as related to the dose producing the first statistically significant increase in uterine weights, and the maximum increase in uterine weight. Substantive performance differences were not observed between the uterotrophic bioassay versions or among the standardized protocols, and these were judged to be qualitatively equivalent. It is noteworthy that these results were reproducible under a variety of different experimental conditions (e.g., animal strain, diet, housing, bedding, vehicle, animal age), indicating that the bioassay's performance as a screen is robust. In conclusion, both the intact, immature, and adult OVX versions, and all protocols appear to be reproducible and transferable across laboratories and are able to detect weak estrogen agonists.
format Text
id pubmed-1241659
institution National Center for Biotechnology Information
language English
publishDate 2003
record_format MEDLINE/PubMed
spelling pubmed-12416592005-11-08 The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies. Kanno, Jun Onyon, Lesley Peddada, Shyamal Ashby, John Jacob, Elard Owens, William Environ Health Perspect Research Article The Organisation for Economic Co-operation and Development has completed phase 2 of an international validation program for the rodent uterotrophic bioassay. The purpose of the validation program was to demonstrate the performance of two versions of the uterotrophic bioassay, the immature female rat and the adult ovariectomized rat, in four standardized protocols. This article reports the dose-response studies of the validation program; the coded single-dose studies are reported in an accompanying paper. The dose-response study design used five selected weak estrogen agonists, bisphenol A, genistein, methoxychlor, nonylphenol, and o,p -DDT. These weak agonists were administered in a prescribed series of doses to measure the performance and reproducibility of the protocols among the participating laboratories. All protocols successfully detected increases in uterine weights when the weak agonists were administered. Within each protocol, there was good agreement and reproducibility of the dose response among laboratories with each substance. Substance-specific variations were observed in the influence of the route of administration on the uterine response, the potency as related to the dose producing the first statistically significant increase in uterine weights, and the maximum increase in uterine weight. Substantive performance differences were not observed between the uterotrophic bioassay versions or among the standardized protocols, and these were judged to be qualitatively equivalent. It is noteworthy that these results were reproducible under a variety of different experimental conditions (e.g., animal strain, diet, housing, bedding, vehicle, animal age), indicating that the bioassay's performance as a screen is robust. In conclusion, both the intact, immature, and adult OVX versions, and all protocols appear to be reproducible and transferable across laboratories and are able to detect weak estrogen agonists. 2003-09 /pmc/articles/PMC1241659/ /pubmed/12948896 Text en
spellingShingle Research Article
Kanno, Jun
Onyon, Lesley
Peddada, Shyamal
Ashby, John
Jacob, Elard
Owens, William
The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies.
title The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies.
title_full The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies.
title_fullStr The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies.
title_full_unstemmed The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies.
title_short The OECD program to validate the rat uterotrophic bioassay. Phase 2: dose-response studies.
title_sort oecd program to validate the rat uterotrophic bioassay. phase 2: dose-response studies.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1241659/
https://www.ncbi.nlm.nih.gov/pubmed/12948896
work_keys_str_mv AT kannojun theoecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT onyonlesley theoecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT peddadashyamal theoecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT ashbyjohn theoecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT jacobelard theoecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT owenswilliam theoecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT kannojun oecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT onyonlesley oecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT peddadashyamal oecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT ashbyjohn oecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT jacobelard oecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies
AT owenswilliam oecdprogramtovalidatetheratuterotrophicbioassayphase2doseresponsestudies